| University of Dundee, Bachelor of Medical Science |
Anthony Quinn is responsible for Synageva’s research and development including its clinical programs and strategies, and biomedical and regulatory affairs. He joins Synageva from Roche where, most recently, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation. While at Roche, Anthony managed programs in rheumatology and respiratory indications in exploratory development, and biomarker and translational medicine activities in the late clinical and registration phase for MabTheraâ„¢/Rituxanâ„¢, Actemraâ„¢ and ocrelizumab. Dr. Quinn joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capacity at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (MD) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his PhD there. He completed a postdoctoral fellowship at UCSF and is a fellow of the Royal College of Physicians London.
